INVESTIGATION OF THE FREQUENCY OF CONTAMINATION OF THE ORAL CAVITY WITH CANDIDA FUNGI AND THEIR SENSITIVITY TO ANTIFUNGAL DRUGS IN CHILDREN WITH BRONCHIAL ASTHMA WHO USE INHALED GLUCOCORTICOSTEROIDS FOR A LONG TIME

Abstract

Bronchial asthma is a chronic inflammatory disease of the respiratory tract that causes the development of bronchial hyperreactivity, which leads to repeated episodes of wheezing, expiratory shortness of breath, chest congestion and coughing, increasing at night or early in the morning. The main groups of drugs for the basic therapy of bronchial asthma are inhaled glucocorticosteroids in the form of individual drugs or in combination with anticholinergic or B-2 agonists. Preparations of inhaled glucocorticosteroids have a number of side effects, one of which is oropharyngeal candidiasis, which often occurs according to a number of instructions (>1/100,<1/10). This is due to the fact that inhaled glucocorticosteroids create favorable conditions for the growth of yeast-like fungi of the genus Candida in the oral cavity and pharynx, due to the suppression of the protective functions of macrophages, neutrophils and T-lymphocytes on the surface of the oral mucosa, as well as due to the appearance of dryness of the oral cavity. In this connection, IGCS preparations have instructions for use. Namely, taking into account the risk of oropharyngeal candidiasis, the patient should thoroughly rinse his mouth with water after each inhalation of the drug. The purpose of the study is to study the awareness of patients about the prevention and risks of fungal infections of the oral cavity arising from the use of inhaled glucocorticosteroids.